No Carolina / NY / Florida
Ph: 561.316.3330

Nanotein Technologies Launches Revolutionary NK Cell Soluble Activator for Cancer Immunotherapy Research

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • “We are thrilled to provide an easy-to-use, pre-assembled NK cell activator that will open the gates for the rapid advancement of NK cell-based therapies, including CAR-NK therapy, and all of the advantages that come with it.
  • The nanoscale format of the activator’s proprietary protein complex also allows scientists to use sterile filtration, an extremely desirable novelty in NK immunotherapy.
  • NanoSpark™ GROW-NK further benefits the manufacture and expansion of NK cells by completely removing the need for labor-intensive co-culturing of NK cells with irradiated, cancerous feeder cells.

Nanotein Technologies, a trailblazing leader in innovative cell therapy reagents, recently launched their latest addition to the NanoSpark™ product line:  NanoSpark™ GROW-NK Soluble Activator. This reagent enables for the feeder cell free activation and expansion of human Natural Killer (NK) cells, ex vivo, to advance cancer immunotherapy development and manufacturing.

Researchers can use this revolutionary and soluble, protein-based activator to easily expand for a large-volume of high-quality NK cells without needing magnetic components. The nanoscale format of the activator’s proprietary protein complex also allows scientists to use sterile filtration, an extremely desirable novelty in NK immunotherapy.

“The launch of NanoSpark™ GROW-NK Soluble Activator represents a paradigm shift in how we generate innovative NK cell immunotherapies,” says Curtis Hodge, PhD, Co-Founder and CEO of Nanotein. “We are thrilled to provide an easy-to-use, pre-assembled NK cell activator that will open the gates for the rapid advancement of NK cell-based therapies, including CAR-NK therapy, and all of the advantages that come with it.”

NK cell-based cancer therapies are a new, groundbreaking type of adoptive immunotherapy with several notable improvements to traditional T cell-based therapies. NK and CAR-NK therapies are far less likely to cause autoimmune reactions that lead to graft versus host disease (GvHD). In addition, they have cellular receptors, such as CD16, that allow the targeting of cancer cells alongside tumor-specific infused antibodies. This process unleashes highly-effective tumor cell death through antibody-dependant cellular cytotoxicity (ADCC).

NanoSpark™ GROW-NK further benefits the manufacture and expansion of NK cells by completely removing the need for labor-intensive co-culturing of NK cells with irradiated, cancerous feeder cells; the historical approach used to manufacture NK cells. This innovation dramatically reduces the cost, complexity, and, most importantly, risk of introducing malignant biologic material into the patient—a significant clinical safety and regulatory hurdle that Nanotein’s new product eliminates.

More information about Nanotein Technologies and their best-in-class cellular therapy reagents is available on their website: www.nanoteintech.com

Find details on NanoSpark™ GROW-NK Soluble Activator visit here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Abu Dhabi Issues First BioTech Inventor-Class Golden Visa to Catalyze “Made-In-Abu-Dhabi IP” to Rockefeller University Inventor Dr Kambiz Shekdar, PhD

Dr Kambiz Shekdar said: "I gratefully take this opportunity as my solemn commitment to help build up the BioTech sector in Abu Dhabi with the same home-grown can-do-and-have-done record of accomplishment demonstrated by Emirati leadership, its people, and nation, and to do so collegially with the best of the best of the world's human capital across frontier technologies who, like myself, are drawn to the UAE with the thirst to pioneer and build better like only possible in the red-hot entrepreneurial climate of the UAE."

Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups

"We celebrate the growing base of research and technological advances within the region's health and life sciences sector," said Chandra Briggman, President and CEO of Activation Capital.

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

By using this website you agree to accept Medical Device News Magazine Privacy Policy